Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MDGL vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Captures Overall Composite Edge (44.4 HOLD vs 47.6 HOLD), While MDGL Leads 4–1 on Growth & Valuation Pillars

SYRE Overall Winner 6-Pillar Tally: MDGL 4 – 1 SYRE (1 Tie) Matrix Metrics: MDGL 7 – 3 SYRE

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (44.4/100 HOLD vs. 47.6/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. MDGL trades at $423.54 (38.1x Forward P/E, -10.7% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. SYRE 44.4/100 HOLD), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY).
  • Technical & Structure Timing Caution: MDGL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.9); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MDGL vs SYRE
MDGL NASDAQ
Madrigal Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$423.54
-0.9% 1D
Market Cap $9.8B
TTM Revenue $1.43B
Forward P/E 38.1x
Beta / 30D Vol 0.28β · 49% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 53.0 Fund 63.0 Flow 63.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 41
RSI-14: 40.9 · SMA20: $429.32 · SMA50: $473.37
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (MDGL 4 – 1 SYRE)

Columns: Metric · MDGL · SYRE
1. Valuation Multiples MDGL
Forward P/E 38.1x N/M
Trailing P/E 61.4x N/M
PEG Ratio N/M N/M
EV / Revenue 6.8x N/M
2. Growth & Scale MDGL
Revenue Growth (YoY) +50.1% +0.0%
Earnings Growth (YoY) +0.0% -99.7%
TTM Revenue (USD) $1.43B N/A
Market Cap $9.8B $9.8B
3. Profitability & Quality SYRE
Gross Margin 91.0% N/A
Operating Margin -10.7% 0.0%
Net Profit Margin -10.9% 0.0%
Return on Equity (ROE) -24.8% -35.0%
4. Balance Sheet & Cash Flow MDGL
Cash Generation (TTM) -$169M N/A
Cash Flow Margin -11.8% N/A
Net Cash / Leverage $160M Net Cash $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MDGL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 59.0% (13th %ile) 87.9% (10th %ile)
Put/Call OI Skew 0.28x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MDGL (7) vs SYRE (3)
Institutional Metric MDGL SYRE Criterion Row Edge
Market Capitalization
Scale
$9.8B $9.8B Larger Scale MDGL
Trailing P/E Ratio
Valuation
61.4x N/M Lower Multiple MDGL
Forward P/E Ratio
Valuation
38.1x N/M Lower Multiple MDGL
Revenue Growth (YoY)
Growth
+50.1% +0.0% Higher Growth MDGL
Operating Margin (TTM)
Profitability
-10.7% 0.0% Higher Margin SYRE
Net Profit Margin
Profitability
-10.9% 0.0% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-24.8% -35.0% Higher ROE MDGL
52-Week Range Position
Momentum
27% ($354–$615) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
0.28β · 49% Vol 1.75β · 59% Vol Lower Realized Risk MDGL
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite MDGL
Trailing 12M Revenue (USD)
Operating Scale
$1.43B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$169M ($160M Net Cash) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +30.94 pp
MDGL: -5.83% · SYRE: +25.11%
3M Horizon SYRE +11.94 pp
MDGL: -19.23% · SYRE: -7.29%
6M Horizon SYRE +61.54 pp
MDGL: -18.9% · SYRE: +42.64%
1Y Horizon SYRE +359.49 pp
MDGL: -17.75% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDGL vs SYRE. Trailing 12-month operating profitability (MDGL -10.7% vs SYRE 0.0%) and valuation multiples (MDGL 38.1x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MDGL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.43B
Gross Margin91.0%
Op. Margin-10.7%
ROE / Fwd P/E-24.8% · 38.1x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MDGL CONSOLIDATION
157d in phase · OBV DISTRIBUTION
Current IV 59.0%
IV Percentile 13th %ile
Put/Call OI Skew 0.28x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MDGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MDGL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and -10.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MDGL vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Madrigal Pharmaceuticals, Inc. (MDGL) on higher Unified Composite conviction (44.4/100 HOLD vs. 47.6/100 HOLD) after splitting the core matrix 3–7 (led by Profitability & Quality), while MDGL wins 4–1 across the 6-pillar growth and valuation breakdown. MDGL trades at $423.54 (38.1x Forward P/E, -10.7% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MDGL currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. SYRE 44.4/100 HOLD), SYRE captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.7% operating margin) and revenue trajectory (+0.0% vs. +50.1% YoY). Technical & Structure Timing Caution: MDGL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.9); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MDGL leads the Growth & Scale pillar: MDGL posts +50.1% YoY revenue growth and +0.0% YoY earnings growth on $1.43B TTM revenue (91.0% gross margin, -10.7% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MDGL generates $1.43B in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, MDGL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

MDGL screens cheaper on headline valuation multiples. MDGL trades at 38.1x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-11.8% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDGL (-24.8% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MDGL carries 59.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 49% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.